Mark Halvorson

Array ( [id] => 20492657 [patent_doc_number] => 12534520 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-27 [patent_title] => YKL-40-targeting human monoclonal antibody [patent_app_type] => utility [patent_app_number] => 17/753682 [patent_app_country] => US [patent_app_date] => 2020-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 40 [patent_no_of_words] => 2451 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17753682 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16878041 [patent_doc_number] => 11028174 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-06-08 [patent_title] => Bifunctional molecules targeting PD-L1 and TGF-b [patent_app_type] => utility [patent_app_number] => 17/006517 [patent_app_country] => US [patent_app_date] => 2020-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 27 [patent_no_of_words] => 11793 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17006517 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16977668 [patent_doc_number] => 20210221905 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => ANTI-CD73 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/005051 [patent_app_country] => US [patent_app_date] => 2020-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24973 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17005051 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16720144 [patent_doc_number] => 20210087291 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-25 [patent_title] => COMBINATION THERAPY OF T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES AND PD-1 AXIS BINDING ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 16/988540 [patent_app_country] => US [patent_app_date] => 2020-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 86477 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16988540 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17929825 [patent_doc_number] => 20220324950 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => IMMUNE CHECKPOINT INHIBITOR, THERAPEUTIC AGENT FOR IMMUNE CHECKPOINT-RELATED DISEASE, IMMUNOSUPPRESSANT, ANTI-FIBRONECTIN ANTIBODY OR DERIVATIVE THEREOF, FIBRONECTIN ANALOG, KIT FOR DETECTING FIBRONECTIN OR PARTIAL PROTEIN THEREOF, AND METHOD FOR DETECTING FIBRONECTIN OR PARTIAL PROTEIN THEREOF [patent_app_type] => utility [patent_app_number] => 17/634424 [patent_app_country] => US [patent_app_date] => 2020-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13800 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17634424 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17945815 [patent_doc_number] => 20220332832 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => COMBINED CANCER THERAPY OF ANTI-GALECTIN-9 ANTIBODIES AND CHEMOTHERAPEUTICS [patent_app_type] => utility [patent_app_number] => 17/631378 [patent_app_country] => US [patent_app_date] => 2020-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43296 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17631378 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16762377 [patent_doc_number] => 20210107958 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => GLYPICAN EPITOPES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/939729 [patent_app_country] => US [patent_app_date] => 2020-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18637 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16939729 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17982631 [patent_doc_number] => 20220348667 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => Specific ACKR2 Modulators for Use in Therapy [patent_app_type] => utility [patent_app_number] => 17/620281 [patent_app_country] => US [patent_app_date] => 2020-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24834 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17620281 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17853123 [patent_doc_number] => 20220283165 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => Methods of Enhancing Immunogenicity of Cancers [patent_app_type] => utility [patent_app_number] => 17/625264 [patent_app_country] => US [patent_app_date] => 2020-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17544 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17625264 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17828516 [patent_doc_number] => 20220265820 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => TUMOR IMMUNOTHERAPY USING SINDBIS VIRAL VECTORS AND AGONIST MONOCLONAL ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/625326 [patent_app_country] => US [patent_app_date] => 2020-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 66036 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17625326 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16596660 [patent_doc_number] => 20210023191 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => VACCINE COMPOSITIONS COMPRISING TRYPTOPHAN 2,3-DIOXYGENASE OR FRAGMENTS THEREOF [patent_app_type] => utility [patent_app_number] => 16/922604 [patent_app_country] => US [patent_app_date] => 2020-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25178 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16922604 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16420464 [patent_doc_number] => 20200345662 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => MUSCULAR ATROPHY-INDUCING AGENT USING HYPOMETABOLISM-INDUCING SUBSTANCE T1AM, AND USE THEREOF IN TREATING MUSCULAR HYPERTROPHY [patent_app_type] => utility [patent_app_number] => 16/922432 [patent_app_country] => US [patent_app_date] => 2020-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8717 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16922432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18590256 [patent_doc_number] => 11739139 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-29 [patent_title] => Monoclonal antibodies against Claudin-18 for treatment of cancer [patent_app_type] => utility [patent_app_number] => 16/919969 [patent_app_country] => US [patent_app_date] => 2020-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 64 [patent_no_of_words] => 38062 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16919969 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18361500 [patent_doc_number] => 20230143091 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-11 [patent_title] => COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/620036 [patent_app_country] => US [patent_app_date] => 2020-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25696 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17620036 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16555804 [patent_doc_number] => 20210000952 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 16/904511 [patent_app_country] => US [patent_app_date] => 2020-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62984 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16904511 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17775064 [patent_doc_number] => 20220241413 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => COMBINATION THERAPIES USING CD-38 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/617811 [patent_app_country] => US [patent_app_date] => 2020-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48160 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17617811 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17762664 [patent_doc_number] => 20220236276 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => METHODS FOR MODULATING A TREATMENT REGIMEN [patent_app_type] => utility [patent_app_number] => 17/616519 [patent_app_country] => US [patent_app_date] => 2020-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13414 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616519 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18642420 [patent_doc_number] => 11766473 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-26 [patent_title] => Therapeutic cancer vaccine containing tumor-associated neoantigens and immunostimulants in a deliver system [patent_app_type] => utility [patent_app_number] => 16/881580 [patent_app_country] => US [patent_app_date] => 2020-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 6807 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16881580 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17913266 [patent_doc_number] => 20220315661 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-06 [patent_title] => DOSAGE REGIMENS FOR A COMBINATION OF ANTI-DR5 ANTIBODIES FOR USE IN TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/609359 [patent_app_country] => US [patent_app_date] => 2020-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36656 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17609359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17733148 [patent_doc_number] => 20220218607 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => STABLE, LOW-VISCOSITY ANTIBODY FORMULATIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/604890 [patent_app_country] => US [patent_app_date] => 2020-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47415 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -82 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17604890 [rel_patent_id] =>[rel_patent_doc_number] =>)